CClinicalTrials.gg
CompletedNCT06992037DUOUpdated Dec 26, 2025

An Ambispective Registry Study Comparing Clinical Outcomes of Surgical Interventions for the Treatment of Nasal Airway Obstruction.

An observational study in Nasal Airway Obstruction, sponsored by Aerin Medical. Completed at 1 site in United States. Open to participants aged 22 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-12-26.

Sponsored by Aerin Medical · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,110
Ages
22 Years to 85 Years
Sex
All
01

Study summary

The purpose of this study is to assess and compare the clinical outcomes associated with common surgical interventions for the treatment of nasal airway obstruction (NAO).

Read the detailed description

This is a multicenter, ambispective registry study. The study will include assessment of prospective, long term outcomes by remote administration of patient reported outcome questionnaires. Participants identified in Part 1 of the study with outcomes available for at least 12 months following their surgical procedure for nasal airway obstruction will be identified by the treating physician and invited to participate in the long-term follow-up study. Participants agreeing to participate will be asked to complete a series of questions about their health experience following their surgery and will be asked to complete select health outcome questionnaires using a secure electronic survey platform.

02

Conditions studied

  • Nasal Airway Obstruction

Browse trials for

03

Who can participate

Ages eligible
22 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with nasal airway obstruction that had either a functional rhinoplasty or septoturbinoplasty within the time frame of January 01, 2013 to December 31, 2023 or a TCRF procedure between the dates of November 19, 2015 to December 31, 2023.

Inclusion criteria

  • Age 22 to 85 years old (inclusively).
  • Sought treatment at the clinic for nasal airway obstruction.
  • Had either a functional rhinoplasty or septoturbinoplasty within the time frame of January 01, 2013 to December 31, 2023 or a Temperature-Controlled Radiofrequency (TCRF) procedure between the dates of November 19, 2015 to December 31, 2023.
  • Has access to a mobile device, tablet, or computer with internet access and has access to an email address.
  • Willing and able to provide consent.
  • Willing and able to complete the survey, including patient-reported outcome measures.
  • Willing and able to comply with the patient-specific requirements outlined in the study protocol.

Exclusion criteria

Exclusion Criteria:

  • Had extreme nasal pathology or a history of extreme nasal injuries.
  • Had cosmetic rhinoplasty with no functional component.
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,110 participants (actual)
Target follow-up
1 Day
Patient registry
Yes

Groups and cohorts

  • Functional Rhinoplasty

    Patients received a non-study/Standard of Care Functional Rhinoplasty within the past 5 years

  • Septoplasty

    Patients received a non-study/Standard of Care Septoplasty within the past 5 years

  • Vivaer

    Patients received a Vivaer procedure (radiofrequency) within the past 5 years

  • Rhinaer

    Patients received a Rhinaer procedure (radiofrequency) within the past 5 years

05

What researchers measure

Primary outcomes

  1. Nasal Obstruction Symptom Scale (NOSE) Score

    The NOSE survey is a disease-specific questionnaire designed to measure nasal obstruction. It is commonly used in otolaryngology practice to provide an objective measure of nasal obstruction. Patients rate on a 0-4 scale questions regarding congestion, ability to get air in nose during exercise, and others. Scores result in symptom severity classes of mild, moderate, severe or extreme NAO.

    Time frame: Jan 2013 - Dec 2025

  2. 22-Item Sinonasal Nasal Outcome Test (SNOT-22)

    The The Sino-Nasal Outcome Test (SNOT-22) Questionnaire is a validated patient-reported outcome measure established to delineate the presence and severity of sinonasal disorders. It is a widely used questionnaire for assessing the impact of chronic rhinosinusitis on a patient's quality of life. Minimum possible score: 0; Maximum possible score: 110. Higher scores indicate: A worse outcome, meaning more severe symptoms and a greater negative impact on quality of life.

    Time frame: Jan 2013 - Dec 2025

  3. Standard Cosmesis and Health Outcomes Survey (SCHNOS)

    The SCHNOS survey is a validated 10-item survey with two-domains (nasal obstruction and nasal cosmesis) patient-reported outcomes survey designed to evaluate both functional and cosmetic components of rhinoplasty. Minimum possible score: 0, Maximum possible score: 40. Higher scores indicate: A better outcome, meaning improved nasal function and cosmesis.

    Time frame: Jan 2013 - Dec 2025

  4. Short Form-12 (SF-12 version 1)

    SF-12 is a 12 question self-reported outcome measure assessing the impact of health on an individual's everyday life. It includes questions in 8 domains: limitations in physical activities due to health problems, limitations in social activities because of physical or emotional problems, limitations on usual role activities because of physical or emotional health problems, bodily pain, general mental health, vitality, and general health perceptions. A score above 50 indicates better than average health-related quality of life and scores less than 50 suggest below-average health. Minimum possible score: 0, Maximum possible score: 100. Higher scores indicate: A better outcome, meaning improved health-related quality of life

    Time frame: Jan 2013 - Dec 2025

  5. Mini-Rhinoconjunctivitis Quality of Life Score (Mini-RQLQ)

    The mini-RQLQ is a self-administered questionnaire that measures functional impairments that are most troublesome to adult patients because of their rhinoconjunctivitis. This instrument has 14 questions in 5 domains: activity limitation, practical problems, nose symptoms, eye symptoms and non-nose/eye symptoms). Minimum possible score: 0, Maximum possible score: 42. Higher scores indicate: A worse outcome, meaning more severe symptoms and a greater negative impact on quality of life.

    Time frame: Jan 2013- Dec 2025

  6. Epworth Sleepiness Scale (ESS)

    The ESS is a validated widely used self-administered screening questionnaire that evaluates excessive daytime sleepiness.

    Time frame: Jan 2013 - Dec 2025

  7. Change in Medication Dose

    Change in the dose from prior to procedure to post procedure of medication used for treating Nasal Airway Obstruction Symptoms

    Time frame: Jan 2013 - Dec 2025

  8. Change in Medication Frequency

    Change in the frequency of use (prior to procedure to post procedure) of medication used for treating Nasal Airway Obstruction Symptoms

    Time frame: Jan 2013 - Dec 2025

  9. Change in use of Nasal Airway Obstruction Devices

    Change in use of devices used for Nasal Airway Obstruction from prior to procedure to Post Procedure

    Time frame: Jan 2013 - Dec 2025

06

Study locations

1 site
  • Chicago Nasal & Sinus Center
    Chicago, Illinois 60602, United States
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT06992037
Lead sponsor
Aerin Medical
Responsible party
Sponsor
First posted
May 28, 2025
Start date
Mar 14, 2025
Primary completion
Jul 21, 2025
Completion
Jul 21, 2025
Last update
Dec 26, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion